|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Alzheimer's disease (AD) has been associated with up-regulation of pro-inflammatory cytokines (e.g., specific gene variants for TNF-alpha; IL-6; IFN-gamma) and low plasma levels of cyanocobalamin (vitamin B12).
|
20110595 |
2010 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 in cerebellum was detectable in all AD and DS patients, but only three out of nine controls.
|
11258753 |
2001 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 is a multifunctional inflammatory cytokine which possibly acts as a mediator in the local immune response in the brain of AD patients.
|
14739540 |
2004 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease.
|
15193763 |
2004 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 (IL-6) is a cytokine shown to affect brain function and to be involved in pathological neurodegenerative disorders such as Alzheimer's disease (AD).
|
15265638 |
2004 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 (IL-6), a pleiotropic inflammatory cytokine, was reported to be associated with both increased A beta aggregation and the appearance of hyperphosphorylated tau in AD brain.
|
20667498 |
2010 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 (IL-6) has previously been shown to participate in neurodegenerative processes including Alzheimer's disease.
|
8550818 |
1995 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.
|
26545630 |
2016 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A single-nucleotide polymorphism (SNP) in the promoter region of the interleukin-6 (IL-6) gene at position -174 (G>C) has been reported to be associated with a variety of major diseases, such as Alzheimer disease, atherosclerosis, and cardiovascular disease, cancer, non-insulin-dependent diabetes mellitus, osteoporosis, sepsis, and systemic-onset juvenile chronic arthritis.
|
15364891 |
2004 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control.
|
30630955 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally cytokines, such as interleukin-1alpha (IL-1alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) are co-localized to senile plaques, a neuropathological hallmark of AD.
|
12399113 |
2002 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for a large set of confounders, including the use of anti-inflammatory drugs, only higher LBP levels were significantly associated with a 30% higher odds of developing AD over 12 years (OR 1.30, 95% CIs [1.07-1.59]), regardless of IL6 levels.
|
31450497 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
After nine months of treatment in APP/PS1 double-transgenic mice, scutellarin significantly improves behavior, reduces soluble and insoluble Aβ levels in the brain and plasma, decreases Aβ plaque associated gliosis and levels of proinflammatory cytokines TNF-α and IL-6, attenuates neuroinflammation, displays anti-amyloidogenic effects, and highlights the beneficial effects of intervention on development or progression of AD-like neuropathology.
|
29642616 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, correlation results of IL1 and IL6 suggest stronger inflammatory effects in LOBD than in AD.
|
28670271 |
2017 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alterations in extracellular matrix proteins in addition to increasing amount of hippocampal IL6 and iron in the early stages of AD may reveal inflammation-mediated iron dyshomeostasis in the early stages of neurodegeneration.
|
29376847 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Are there interactions of other genes with IL6 that affect the development and progression of AD?
|
11754993 |
2002 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because IL-6 has been implicated in the etiopathology of different human diseases including multiple myeloma, rheumatoid arthritis, multiple sclerosis, acquired immunodeficiency syndrome dementia complex, and Alzheimer's disease, its inhibition may be of therapeutic interest.
|
9523575 |
1998 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Blood levels of CRP and IL-6 are also associated with higher risk of Alzheimer disease and cognitive decline during aging.
|
17430245 |
2007 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
By virological and molecular analyses we found: i) HSV-1 spreading and replication in different brain regions after thermal stress-induced virus reactivations; ii) accumulation of AD hallmarks including amyloid-β protein, tau hyperphosphorylation, and neuroinflammation markers (astrogliosis, IL-1β and IL-6).
|
30870531 |
2019 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
C-reactive protein (HR = 1.37 [1.05; 1.78]), interleukin-6 (HR = 1.40 [1.13; 1.73]), α1-antichymotrypsin (HR = 1.54 [1.14; 2.80]), lipoprotein-associated phospholipase A2 activity (HR = 1.40 [1.03; 1.90]), and fibrinogen were each associated with all-cause dementia, but neither was significantly associated with AD.
|
29605221 |
2018 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Current research was directed at assessing beta amyloid, cytokines (IL-6, IL-10 and TNF alpha) plasma levels in women with AD.
|
18283248 |
2008 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokine interleukin-6 (IL-6) is thought to play a role in Alzheimer's disease (AD) pathogenesis.
|
20197062 |
2010 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elderly with depression have higher IL-6 than controls, while those with Alzheimer's disease did not have higher peripheral inflammatory markers.
|
30104698 |
2018 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of cytokines have been detected in brains of Alzheimer's disease (AD) patients, and altered peripheral levels of IL-1beta, TNFalpha and IL-6 have been reported in these patients.
|
14975597 |
2004 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
ELISPOT assays were used to measure pro-inflammatory cytokine (TNF-alpha; IL-6; IL-1beta; IFN-gamma) production in peripheral blood mononuclear cell (PBMC) supernatant from AD patients.
|
23463934 |
2013 |